# Cellectis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellectis

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.cellectis.com
- Total disclosed funding: $14M
- Latest round: Series C (Jun 1, 2005)
- Investors on record: 4

## About

Cellectis SA is a clinical-stage biotechnology company specializing in gene-edited CAR T-cell therapies, utilizing its proprietary TALEN® technology to develop innovative immunotherapy products aimed at treating various cancers.Founded in 1999, Cellectis SA operates out of Paris, France, focusing on developing advanced gene-editing therapies for cancer treatment. The company completed an IPO in March 2015, raising USD 229 mn from the sale of American Depository Receipts. The CEO, Andre Choulika, has a history of leadership in biotechnology ventures, underscoring the company’s commitment to advancing cancer therapies globally. Cellectis has engaged in a total of 8 deals, with AstraZeneca being a notable investor in its latest funding round, the LP Direct PIPE, amounting to USD 140 mn.Cellectis specializes in developing innovative gene-edited CAR T-cell therapies, primarily leveraging its proprietary TALEN® technology platform to create allogeneic 'off-the-shelf' immunotherapy products. These therapies are designed to provide new treatment options for cancer patients, specifically targeting B-cell malignancies like relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell Non-Hodgkin lymphoma. Cellectis' CAR T therapies utilize gene-edited T-cells derived from healthy donors to mitigate challenges associated with traditional CAR T treatments, such as Graft vs. Host Disease and rejection. The company’s offerings, including product candidates like UCART20x22 and UCART22, are aimed at broad patient populations and have been presented at significant scientific conferences, showing active engagement with the global medical community. Cellectis’ products are positioned for markets across North America and Europe, enhancing accessibility for a range of healthcare providers and patients.In 2010, Cellectis reported a revenue of USD 10,836,282, alongside an EBITDA of USD -13,778,241. The company generates revenue through strategic partnerships with pharmaceutical firms such as Allogene and AstraZeneca, likely involving revenue-sharing agreements and milestone payments tied to the development of therapies. These collaborations enable Cellectis to leverage its expertise in gene editing to support the development of customized therapies for partners, while specific pricing plans for products like UCART22 remain undisclosed.Cellectis is focused on expanding its portfolio of gene-edited CAR T-cell therapies, with plans to launch new products designed to address unmet medical needs in oncology. The company aims to strengthen its presence in North America and Europe, capitalizing on its recent IPO funding of USD 229 mn to support pipeline development and market entry strategies. The proceeds from the LP Direct PIPE funding, completed in March 2015, will be utilized to enhance research activities, facilitate clinical trials, and expand commercial partnerships, reinforcing Cellectis' commitment to delivering innovative cancer therapies.

## Funding rounds

- Series C, Jun 1, 2005, $6.8M — Idinvest Partners, Odyssee Venture, Edmond de Rothschild Asset Management, BankInvest Biomedical Venture
- Series B, May 1, 2002, $7M — Idinvest Partners, Odyssee Venture, Edmond de Rothschild Asset Management, BankInvest Biomedical Venture

## Investors

- Idinvest Partners (https://capitalatlas.ai/funds/idinvest-partners) — Series B, Series C
- Odyssee Venture (https://capitalatlas.ai/funds/odyssee-venture) — Series B, Series C
- Edmond de Rothschild Asset Management (https://capitalatlas.ai/funds/edmond-de-rothschild-asset-management) — Series B, Series C
- BankInvest Biomedical Venture — Series B, Series C